Suchergebnisse - "Corso, Alessandro"

PubPharm (14)

1

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics

enthalten in: European journal of haematology | 2022

von Richardson, P. | Schjesvold, F. | Weisel, K. | +25

2

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM) : outcomes by prior treatment at first relapse

enthalten in: Leukemia | 2021

von Dimopoulos, M. | Weisel, K. | Moreau, P. | +17

3

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2019

von Richardson, P. | Oriol, A. | Beksac, M. | +123

CommentIn: Lancet Oncol. 2019 Jun;20(6):743-744. - PMID 31097404

4

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2018

von Mohty, M. | Terpos, E. | Mateos, M. | +130

5

Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study

enthalten in: Leukemia & lymphoma | 2017

von Pozzi, S. | Gentile, M. | Sacchi, S. | +16

6

Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma

enthalten in: British journal of haematology | 2013

von Mangiacavalli, S. | Pochintesta, L. | Cocito, F. | +4

7

Continuous lenalidomide treatment for newly diagnosed multiple myeloma

enthalten in: The New England journal of medicine | 2012

von Palumbo, A. | Hajek, R. | Delforge, M. | +86

ErratumIn: N Engl J Med. 2012 Jul 19;367(3):285

8

Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma

enthalten in: Leukemia & lymphoma | 2012

von Mangiacavalli, S. | Albani, G. | Caravita, T. | +7

CommentIn: Leuk Lymphoma. 2011 Nov;52(11):2043-4. - PMID 21740295

9

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

enthalten in: Haematologica | 2010

von Harousseau, J. | Dimopoulos, M. | Wang, M. | +9

10

Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects

enthalten in: Leukemia research | 2009

von Corso, A. | Zappasodi, P. | Barbarano, L. | +9